Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 34 Show results per page	View Search Criteria \| Help With Results

Last Modified: 4/9/2008 First Published: 10/1/1999


1.		Phase I/II Pilot Study of p53 Vaccine in Patients With Adenocarcinoma of the Ovary Who Have No Evidence of Disease or Marker Disease Only

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NCI-99-C-0137 NCI-NMOB-9903, NCI-T99-0074, T99-0074, NCT00019903

Last Modified: 12/27/2008 First Published: 3/1/2001


2.		Phase I/II Study of Immunization With Autologous In Vitro-Treated Tumor Cells and Dendritic Cells in Combination With Sargramostim (GM-CSF) in Patients With Stage IV or Recurrent Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 16				Other				HOAG-VACCINE-MEL NCI-V01-1646, NCT00012064

Last Modified: 12/27/2008 First Published: 4/1/2001


3.		Phase I/II Study of Immunization With In Vitro-Treated Autologous Tumor Cells and Dendritic Cells With Sargramostim (GM-CSF) in Patients With Stage III or IV or Recurrent Renal Cell Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				16 and over				Other				HOAG-VACCINE-RN NCI-V01-1647, NCT00014131

Last Modified: 1/14/2005 First Published: 8/1/2001


4.		Phase I/II Study of Alpha-Fetoprotein Peptide-Pulsed Autologous Dendritic Cells in HLA-A*0201-Positive Patients With Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				NCI				UCLA-0001026 NCI-G01-1997, NCT00022334

Last Modified: 7/23/2007 First Published: 11/24/2002


5.		Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40-Ligand Treatment in Patients With HLA-A1 and/or HLA-A2.1 Positive Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				Other				ERLANGEN-1490 EU-20232, NCT00053391

Last Modified: 6/27/2007 First Published: 7/23/2005


6.		Phase I/II Study of Vaccine Therapy Comprising Autologous Dendritic Cells Transfected With Autologous Polymerase Chain Reaction-Amplified Tumor RNA in Patients With Stage IV Cutaneous Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				Other, Pharmaceutical / Industry				ERLANGEN-DERMA-ER-DC-07 EU-20513, ARGOS-ERLANGEN-DERMA-DC-07, NCT00126685


7.		Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				AGS-003-004 Bukowski-8077, Logan-0506-05, Drabkin-05-0167, White-04-05-01A, Figlin-05-03-099-01, NCT00272649


8.		A Clinical Trial That Looks at the Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients’ Own Immune Cells.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				RDA 0466 NCT00289341


9.		Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Temporarily closed				18 and over				Other				04-178 NIH R01-DE13818, NCT00377247

Last Modified: 5/3/2006


10.		Phase II Pilot Study of Autologous T-Cell Transplantation With Vaccine-Driven Expansion of Antitumor Effectors After Cytoreductive Therapy in Patients With Metastatic Pediatric Sarcomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				35 and under at initial diagnosis				NCI				NCI-97-C-0052 NCI-T96-0038, T96-0038, NCT00019266

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute